Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation

Bryant J, Cave1 C, Mihaylova B, Chase D, McIntyre L, Gerard K, Milne R

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
This review considers the clinical effectiveness and cost-effectiveness of growth hormone (GH) therapy in children with GH deficiency (GHD), Turner syndrome (TS), chronic renal failure (CRF), Prader-Willi syndrome (PWS) or idiopathic short stature (ISS).

Authors' conclusions
GH is already prescribed in the UK. However, a full course of treatment is expensive. Given that only a minority of children with licensed conditions are currently receiving GH, the budgetary impact of large increases in prescribing would be substantial. If GH were to be prescribed to any significant proportion of children with ISS, the budgetary impact would be very substantial because this group of children is much larger than the others.

Project page URL
http://www.hta.ac.uk/1240

INAHTA brief and checklist

Indexing Status
Subject indexing assigned by CRD

MeSH
Child; Costs and Cost Analysis; Growth Disorders /drug therapy; Growth Hormone

Language Published
English

Country of organisation
England

Address for correspondence
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk

AccessionNumber
32002000909